- Article
High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction
- Takayuki Takahashi,
- Hideyuki Terazono,
- Takayuki Suetsugu,
- Hideki Sugawara,
- Junko Arima,
- Mina Nitta,
- Toru Tanabe,
- Kayu Okutsu,
- Ryuji Ikeda and
- Keiko Mizuno
- + 2 authors
Afatinib is used to treat non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation as a second-generation EGFR-tyrosine kinase inhibitor (TKI). Early prediction of adverse effects based on the pharmacokinetics of...